n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Trial Of Iclusig

ARIAD Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Trial Of Iclusig

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced enrollment of fifty percent of the patients planned in its randomized Phase 3 trial of Iclusig ® (ponatinib) in adult patients with newly diagnosed ...

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

ARIAD Reports Second Quarter 2013 Financial Results And Development Progress

ARIAD Reports Second Quarter 2013 Financial Results And Development Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2013, including revenue from Iclusig ® (ponatinib), which is approved by the U.

Quick Take: Biotech's Next Big Thing Is Earnings

Quick Take: Biotech's Next Big Thing Is Earnings

It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, senior columnist at TheStreet.

Biotech's Next Big Thing: Earnings

Biotech's Next Big Thing: Earnings

It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.

Ariad Pharma: Three Hurdles For Long-Term Win

Ariad Pharma: Three Hurdles For Long-Term Win

Ariad must navigate three challenges in order for its leukemia drug Iclusig to become a blockbuster.

Ariad Pharmaceuticals (ARIA): Today's Featured Health Care Laggard

Ariad Pharmaceuticals (ARIA): Today's Featured Health Care Laggard

Ariad Pharmaceuticals was a leading decliner within the health care sector, falling $0.65 (-3.2%) to $19.37 on light volume

ARIAD To Host Conference Call And Webcast Discussion Of Second Quarter 2013 Financial Results On August 7, 2013

ARIAD To Host Conference Call And Webcast Discussion Of Second Quarter 2013 Financial Results On August 7, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2013 financial results on Wednesday, August 7, 2013, before the market opens.

ARIAD Names Sarah J. Schlesinger, M.D. Of Rockefeller University To Its Board Of Directors (Photo: Business Wire)

ARIAD Names Sarah J. Schlesinger, M.D. Of Rockefeller University To Its Board Of Directors (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Sarah J.

ARIAD Announces Marketing Authorization For Iclusig® (ponatinib) In The European Union

ARIAD Announces Marketing Authorization For Iclusig® (ponatinib) In The European Union

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the European Commission (EC) has granted a marketing authorization for Iclusig ® (ponatinib) as an orphan medicinal product for two ...

ARIAD Pharmaceuticals (ARIA) Shares Cross Above 200 DMA

ARIAD Pharmaceuticals (ARIA) Shares Cross Above 200 DMA

In trading on Monday, shares of ARIAD Pharmaceuticals, Inc. crossed above their 200 day moving average of $20.25, changing hands as high as $20.26 per share.

ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.

ARIAD Honored With Gold Stevie® Awards As Pharmaceutical Company Of The Year At 2013 American Business Awardssm

ARIAD Honored With Gold Stevie® Awards As Pharmaceutical Company Of The Year At 2013 American Business Awardssm

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was honored with two Gold Stevie ® Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, ...

ARIAD Announces Webcast Of Its Annual Shareholders Meeting

ARIAD Announces Webcast Of Its Annual Shareholders Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 20, 2013 and can be accessed by visiting the investor relations section of the...

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals was a leading decliner within the drugs industry, falling $0.30 (-1.6%) to $18.96 on light volume

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Winner

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Winner

Ariad Pharmaceuticals was a winner within the drugs industry, rising $0.90 (5.1%) to $18.43 on heavy volume

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) is trading at unusually high volume Thursday with 5.9 million shares changing hands. It is currently at two times its average daily volume and trading down 42 cents (-2.5%).

10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine

Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine

Ariad's Harvey Berger holds a 90-minute call to refute concerns about toxicity of Iclusig.

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) is trading at unusually high volume Wednesday with 5.7 million shares changing hands. It is currently at 2.1 times its average daily volume and trading down 98 cents (-5.6%).

Ariad's Leukemia Drug Toxic, Survey Says

Ariad's Leukemia Drug Toxic, Survey Says

Ariad shares fall as oncologist survey shows concern about patient tolerance for its leukemia drug Iclusig.

Most Profitable Second Quarter Biotech Stocks

Most Profitable Second Quarter Biotech Stocks

A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.

Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day

Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day

Ariad Pharmaceuticals was a leading decliner within the drugs industry, falling 23 cents (-1.3%) to $18.08 on light volume.

Ariad Pharma Falls On Weak Leukemia Drug Prescriptions

Ariad Pharma Falls On Weak Leukemia Drug Prescriptions

One investor short Ariad calls Iclusig a "dirty drug" because side effects are turning off doctors and patients.

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) is trading at unusually high volume Monday with 5.3 million shares changing hands. It is currently at 2.1 times its average daily volume and trading down $1.04 (-5.4%).

ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union

ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing ...

ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting

ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, ...

ARIAD To Present At Barclays Global Healthcare Conference

ARIAD To Present At Barclays Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at Barclays Global Healthcare Conference being held in Miami.

ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference

ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 33 rd Annual Health Care Conference being held in Boston.